Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease
© 2024. The Author(s)..
BACKGROUND: Parkinson's disease (PD) is a common and costly progressive neurodegenerative disease of unclear etiology. A disease-modifying approach that can directly stop or slow its progression remains a major unmet need in the treatment of PD. A clinical pharmacology-based drug repositioning strategy is a useful approach for identifying new drugs for PD.
METHODS: We analyzed claims data obtained from the National Health Insurance Service (NHIS), which covers a significant portion of the South Korean population, to investigate the association between antihistamines, a class of drugs commonly used to treat allergic symptoms by blocking H1 receptor, and PD in a real-world setting. Additionally, we validated this model using various animal models of PD such as the 6-hydroxydopmaine (6-OHDA), α-synuclein preformed fibrils (PFF) injection, and Caenorhabditis elegans (C. elegans) models. Finally, whole transcriptome data and Ingenuity Pathway Analysis (IPA) were used to elucidate drug mechanism pathways.
RESULTS: We identified fexofenadine as the most promising candidate using National Health Insurance claims data in the real world. In several animal models, including the 6-OHDA, PFF injection, and C. elegans models, fexofenadine ameliorated PD-related pathologies. RNA-seq analysis and the subsequent experiments suggested that fexofenadine is effective in PD via inhibition of peripheral immune cell infiltration into the brain.
CONCLUSION: Fexofenadine shows promise for the treatment of PD, identified through clinical data and validated in diverse animal models. This combined clinical and preclinical approach offers valuable insights for developing novel PD therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Journal of neuroinflammation - 21(2024), 1 vom: 21. Feb., Seite 53 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Jae-Bong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-Synuclein |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 24.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12974-024-03041-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368734528 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368734528 | ||
| 003 | DE-627 | ||
| 005 | 20240229150226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12974-024-03041-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368734528 | ||
| 035 | |a (NLM)38383441 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Jae-Bong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Parkinson's disease (PD) is a common and costly progressive neurodegenerative disease of unclear etiology. A disease-modifying approach that can directly stop or slow its progression remains a major unmet need in the treatment of PD. A clinical pharmacology-based drug repositioning strategy is a useful approach for identifying new drugs for PD | ||
| 520 | |a METHODS: We analyzed claims data obtained from the National Health Insurance Service (NHIS), which covers a significant portion of the South Korean population, to investigate the association between antihistamines, a class of drugs commonly used to treat allergic symptoms by blocking H1 receptor, and PD in a real-world setting. Additionally, we validated this model using various animal models of PD such as the 6-hydroxydopmaine (6-OHDA), α-synuclein preformed fibrils (PFF) injection, and Caenorhabditis elegans (C. elegans) models. Finally, whole transcriptome data and Ingenuity Pathway Analysis (IPA) were used to elucidate drug mechanism pathways | ||
| 520 | |a RESULTS: We identified fexofenadine as the most promising candidate using National Health Insurance claims data in the real world. In several animal models, including the 6-OHDA, PFF injection, and C. elegans models, fexofenadine ameliorated PD-related pathologies. RNA-seq analysis and the subsequent experiments suggested that fexofenadine is effective in PD via inhibition of peripheral immune cell infiltration into the brain | ||
| 520 | |a CONCLUSION: Fexofenadine shows promise for the treatment of PD, identified through clinical data and validated in diverse animal models. This combined clinical and preclinical approach offers valuable insights for developing novel PD therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antihistamine | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a Fexofenadine | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a α-Synuclein | |
| 650 | 7 | |a fexofenadine |2 NLM | |
| 650 | 7 | |a E6582LOH6V |2 NLM | |
| 650 | 7 | |a Oxidopamine |2 NLM | |
| 650 | 7 | |a 8HW4YBZ748 |2 NLM | |
| 650 | 7 | |a alpha-Synuclein |2 NLM | |
| 650 | 7 | |a Terfenadine |2 NLM | |
| 650 | 7 | |a 7BA5G9Y06Q |2 NLM | |
| 700 | 1 | |a Kim, Yujeong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Soo-Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Ha, Tae-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Dong-Kyu |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Dong Won |e verfasserin |4 aut | |
| 700 | 1 | |a So, Minyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Hyun Goo |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Dukyong |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sang Myun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroinflammation |d 2004 |g 21(2024), 1 vom: 21. Feb., Seite 53 |w (DE-627)NLM149680333 |x 1742-2094 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:21 |g month:02 |g pages:53 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12974-024-03041-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 1 |b 21 |c 02 |h 53 | ||